Evaluation of candidemia in children at a university hospital: A retrospective cohort

dc.authorscopusid57221502271
dc.authorscopusid38061964200
dc.authorscopusid56088300100
dc.authorscopusid58066975500
dc.authorscopusid36127430300
dc.authorscopusid6507039290
dc.authorscopusid24921267800
dc.contributor.authorGuner Ozenen, G.
dc.contributor.authorSahbudak Bal, Z.
dc.contributor.authorAvcu, G.
dc.contributor.authorOzkaya Yazici, P.
dc.contributor.authorKarakoyun, M.
dc.contributor.authorMetin, D.Y.
dc.contributor.authorHilmioglu Polat, S.
dc.date.accessioned2024-08-25T18:36:53Z
dc.date.available2024-08-25T18:36:53Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Candidemia is a life-threatening infection in hospitalied children. This study aimed to evaluate candidemia's demographic and clinical characteristics and identify the risk factors and outcomes of Candida albicans (CA) and non-albicans Candida (NAC) spp. Methods: A retrospective cohort was designed to evaluate paediatric patients with candidemia between January 2008 and December 2020. Results: A total of 342 episodes in 311 patients were evaluated. The median age of the patients was 2.1 years (1 month–17 years and 6 months), and 59.6% were male. The prevalence of NAC (67.5%) candidemia was higher than that of CA (32.5%). The most commonly isolated Candida species was Candida parapsilosis (43.3%), followed by C. albicans (32.5%), Candida glabrata (6.1%) and Candida tropicalis (5.0%). The length of hospital stay prior to the positive culture and the total length of hospital stay were longer in the NAC group (p =.003 and p =.006). The neutrophil count was lower in the NAC group (p =.007). In the multivariate analysis, total parenteral nutrition, antifungal prophylaxis and a history of coagulase-negative staphylococci (CoNS) culture positivity in the past month were risk factors for developing candidemia due to NAC (p values were.003,.003 and.045). C. albicans and C. parapsilosis fluconazole resistance were 9.5% and 46.6%, respectively. The rates of amphotericin B resistance were 1.1% and 7.6% in C. albicans and C. parapsilosis, respectively. Mortality (14-day and 30-day) rates did not differ between the groups. Conclusions: A history of CoNS culture positivity in the past month, total parenteral nutrition, and antifungal prophylaxis increases the risk of NAC candidemia. © 2023 Wiley-VCH GmbH.en_US
dc.identifier.doi10.1111/myc.13564
dc.identifier.endpage377en_US
dc.identifier.issn0933-7407
dc.identifier.issue5en_US
dc.identifier.pmid36597951en_US
dc.identifier.scopus2-s2.0-85146326634en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage367en_US
dc.identifier.urihttps://doi.org/10.1111/myc.13564
dc.identifier.urihttps://hdl.handle.net/11454/100787
dc.identifier.volume66en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJohn Wiley and Sons Incen_US
dc.relation.ispartofMycosesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectCandida albicansen_US
dc.subjectCandidemiaen_US
dc.subjectfluconazoleen_US
dc.subjectnon-albicans Candidaen_US
dc.subjectpaediatricsen_US
dc.subjectamphotericin Ben_US
dc.subjectamphotericin B lipid complexen_US
dc.subjectanidulafunginen_US
dc.subjectantibiotic agenten_US
dc.subjectantineoplastic agenten_US
dc.subjectcaspofunginen_US
dc.subjectechinocandinen_US
dc.subjectfluconazoleen_US
dc.subjectimmunosuppressive agenten_US
dc.subjectitraconazoleen_US
dc.subjectmicafunginen_US
dc.subjectposaconazoleen_US
dc.subjectsteroiden_US
dc.subjectvoriconazoleen_US
dc.subjectantifungal agenten_US
dc.subjectadolescenten_US
dc.subjectantifungal resistanceen_US
dc.subjectantifungal susceptibilityen_US
dc.subjectantifungal therapyen_US
dc.subjectArticleen_US
dc.subjectbacterium cultureen_US
dc.subjectCandidaen_US
dc.subjectCandida albicansen_US
dc.subjectCandida dubliniensisen_US
dc.subjectCandida glabrataen_US
dc.subjectCandida inconspicuaen_US
dc.subjectCandida intermediaen_US
dc.subjectCandida parapsilosisen_US
dc.subjectCandida tropicalisen_US
dc.subjectcandidemiaen_US
dc.subjectchilden_US
dc.subjectClavispora lusitaniaeen_US
dc.subjectclinical featureen_US
dc.subjectcoagulase negative Staphylococcusen_US
dc.subjectcohort analysisen_US
dc.subjectcontrolled studyen_US
dc.subjectfemaleen_US
dc.subjectfungus cultureen_US
dc.subjectfungus isolationen_US
dc.subjecthospitalized childen_US
dc.subjecthumanen_US
dc.subjectinfection preventionen_US
dc.subjectinfection risken_US
dc.subjectKluyveromyces marxianusen_US
dc.subjectlength of stayen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmedical historyen_US
dc.subjectMeyerozyma guilliermondiien_US
dc.subjectmonotherapyen_US
dc.subjectmortalityen_US
dc.subjectneutropeniaen_US
dc.subjectneutrophil counten_US
dc.subjectnonhumanen_US
dc.subjectPichia kudriavzeviien_US
dc.subjectprevalenceen_US
dc.subjectprognosisen_US
dc.subjectretrospective studyen_US
dc.subjecttertiary care centeren_US
dc.subjecttotal parenteral nutritionen_US
dc.subjecttreatment outcomeen_US
dc.subjectTurkey (republic)en_US
dc.subjectuniversity hospitalen_US
dc.subjectWickerhamomyces anomalusen_US
dc.subjectCandida albicansen_US
dc.subjectcandidemiaen_US
dc.subjectmicrobial sensitivity testen_US
dc.subjectmicrobiologyen_US
dc.subjectpreschool childen_US
dc.subjectrisk factoren_US
dc.subjectAntifungal Agentsen_US
dc.subjectCandidaen_US
dc.subjectCandida albicansen_US
dc.subjectCandida parapsilosisen_US
dc.subjectCandidemiaen_US
dc.subjectChilden_US
dc.subjectChild, Preschoolen_US
dc.subjectFemaleen_US
dc.subjectHospitals, Universityen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMicrobial Sensitivity Testsen_US
dc.subjectRetrospective Studiesen_US
dc.subjectRisk Factorsen_US
dc.titleEvaluation of candidemia in children at a university hospital: A retrospective cohorten_US
dc.typeArticleen_US

Dosyalar